Northway Biotech
VILNIUS, LITHUANIA / ACCESSWIRE / November 16, 2023 / Northway Group is embarking on a project to establish Europe's largest biotechnology hub, BIO CITY, in Vilnius, the capital of Lithuania. It includes 6 large biotechnological complexes - 4 state-of-the-art GMP manufacturing plants and 2 advanced scientific research centres - that will be built in an area equivalent to 10 football fields. The total investment for this biotech campus is projected to reach approximately 7 billion euros over the next decade.
Northway Group is in the process of constructing Europe's largest biotechnology hub, with the inaugural Gene Therapy Center set to be operational in 2024.
"A science-based economy, supported by bright minds and intelligent entrepreneurs, is the foundation for Lithuania's long-term economic prosperity. In the past, our growth was constrained by a lack of fossil resources, but today, we are boldly moving forward, relying on modern technologies. The new biotechnology hub embodies the direction of Lithuania's innovative economy. It also promises new inventions that will enable people with serious illnesses to become full members of society, thereby reducing exclusion," says the President of the Republic of Lithuania, Gitanas Nausėda.
Prof. Vladas Algirdas Bumelis, founder and CEO of Northway Biotech and Celltechna, key components of the Northway Group, highlighted Lithuania's strong global standing in biotechnology. The aim of the BIO CITY project is to further solidify this position with four advanced biomanufacturing facilities and two innovative research centres, significantly boosting Lithuania's prominence in the international biotech sphere.
The Speaker of the Seimas, parliament of Lithuania, states that the new biotech city being developed in Vilnius will strengthen the competitiveness of our country. "Lithuanian life sciences industry has ambitions and potential to become a global leader in this field: a leader who will significantly contribute to the development of scientific research for the well-being of man, nature and planet, and will facilitate new opportunities to deal with global health, sustainable development and other challenges," says Viktorija Čmilytė-Nielsen.
Vision of BIO CITY: A European Biotechnology Leader
"We envision BIO CITY as a frontrunner in the European biotechnology, by uniquely integrating various biotech segments into a single, synergistic ecosystem. This multifunctional complex will catalyse interdisciplinary collaborations, the quick realisation of ideas and technological advancements. Our unique model, which brings together diverse biotechnology fields in one location, is set to revolutionise the European biotech landscape," said Prof. V. A. Bumelis.
Gene Therapy Centre will Open in 2024
The first facility to open its doors in the biotech hub BIO CITY will be the Gene Therapy Centre, which is currently under construction and is being built by Northway Group's subsidiary, Celltechna. This centre, the first and so far the only one of its kind in the Baltic States, will bolster Lithuania's role in gene therapy, addressing the needs of the 280 million individuals worldwide who are affected by genetic diseases.
"Our state-of-the-art facility will be instrumental in both research and production, offering new treatments for previously incurable diseases. This will not only augment our CDMO (Contract Development and Manufacturing Organisation) capabilities, but also position us for global competition and collaborations," added Prof. V. A. Bumelis.
The Gene Therapy Centre, which is expected to become operational in the second quarter of 2024, will specialise in gene therapy research and GMP manufacturing. Representing an investment of 50 million euros, the facility will span 8,000 square metres and is anticipated to create over 100 high-value jobs. The centre will work in synergy with Northway Biotech. Established in 2004, Northway Biotech is a leading provider of CDMO services in the field of biologics, with a focus on the development and manufacturing of recombinant proteins and antibodies.
A Comprehensive Lithuanian Biotech Hub
By 2030, BIO CITY will see the inauguration of five additional complexes, including centres for R&D and Virology, Life Sciences Industry Smart Services, Stem Cell Research and 3D Bioprinting, as well as two large-scale production centres for mammalian and microbial products. The entire BIO CITY complex will span an area equivalent to 10 football fields, with the total investment expected to reach around 7 billion euros over the next decade.
"We will not only focus on contract development and manufacturing services, but will also invest significantly in the operation of scientific research centres. Scientific activity enhances a country's competitiveness and generates value in various forms, beyond just the economic aspect. Modern biotechnologies, such as gene editing and cell therapies, are advancing rapidly. Lithuania can pride itself on having some of the most talented scientists and robust expertise in these areas. The development of the biotech campus in Vilnius means we are poised to foster new partnerships with innovative startups, research institutions and pharmaceutical companies on a global scale. We are actively seeking partnerships and offer a warm invitation to investors who are enthusiastic about joining this exciting venture," said Prof. V. A. Bumelis.
Upon its completion, BIO CITY is expected to offer employment to approximately 2,100 highly skilled professionals, including scientists, biotechnologists, and medical engineers.
Lithuania is Among the Leaders in the Global Biotechnology Market
The global biotechnology market, currently valued at over 1,130 billion euros, is anticipated to grow to be worth more than 2,775 billion euros by 2030. Lithuania holds a strong position in this market, ranking among the Top 35 innovative countries in the biotechnology field, according to Scientific American Worldview.
"Every year, Lithuania is mentioned in the field of Life Sciences more often, and the ambitious BIO CITY project will contribute to our leadership. Our vision is coming to life - we are talking about world-class Life Sciences infrastructure and a competitive sector capable of building innovative products. In 2022, companies in the sector posted combined revenues of 1.5 billion euros, while exporting their goods to more than 100 countries. Overall, Life Sciences is a leading sector in Lithuania, when it comes to creating and implementing innovative solutions," states Aušrinė Armonaitė, the Minister of the Economy and Innovation.
Over 80 life science companies operate in Lithuania, contributing about 2.5% to the country's GDP. The Northway group, a key player in Lithuania's biotech sector, manages seven companies: five in Lithuania and one each in the UK and the US, with the US entity being recognised as the largest biotech investor from the Baltic region in recent years. Employing more than 200 specialists, these companies provide services to a diverse array of international biopharmaceutical firms, ranging from small to large enterprises, predominantly operating in both Europe and the US.
BIO CITY Contacts:
Vladas Algirdas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
Contact Information:
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
Related Files
BIO CITY LOGO_ORANGE.png
BIO CITY LOGO_BLACK.png
Related Images
SOURCE: Northway Healthcare Group
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/804258/the-largest-biotech-city-in-europe-will-soon-be-built-with-an-investment-amounting-to-7-billion-euros
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Sauce Labs Achieves Milestone Fifth Consecutive ISO 27001 Certification, Reinforcing World-Class Security and Privacy Commitment20.1.2026 09:00:00 CET | Press release
SAN FRANCISCO, CA / ACCESS Newswire / January 20, 2026 / Sauce Labs, the leading provider of Continuous Testing and Cloud-based Software Quality solutions, today announced the successful renewal of its critical ISO/IEC 27001:2022 and ISO 27701:2019 certifications. This achievement marks the fifth consecutive year for the ISO/IEC 27001 (Information Security Management System) and the fourth consecutive year for the ISO 27701 (Privacy Information Management System), solidifying the company's position as a trusted partner for global enterprises. The rigorous, independent audit confirmed Sauce Labs' systematic and robust approach to managing sensitive information and personal data, resulting in zero Minor or Major Nonconformities. "Reaching this five-year milestone with zero nonconformities is a massive validation of our ongoing investment in security and compliance," said Marcia Foley, VP of Global Compliance at Sauce Labs. "For our customers, this renewal is undeniable proof that Sauce L
IXOPAY Launches New TokenEx Packages, Setting the Standard for Token-First Payments in the Era of Agentic Commerce20.1.2026 06:00:00 CET | Press release
New TokenEx packages give merchants a faster, clearer path to secure and independent payments. In parallel, IXOPAY expands its global payments capabilities with new support for Brazil's PIX instant payment system. LEHI, UTAH / ACCESS Newswire / January 20, 2026 / IXOPAY, the enterprise-grade global payment infrastructure platform built for the era of agentic commerce, today announced the launch of three new TokenEx tokenization packages designed to help merchants secure payment data, reduce complexity, and maintain independence across processors, markets, and payment methods. As payments ecosystems become increasingly fragmented, many businesses remain constrained by processor-owned tokens, rigid integrations, and infrastructure that is costly to change. IXOPAY's new TokenEx packages establish tokenization as the foundation for modern payments, giving merchants a standardized, future-ready way to protect data, retain control, and scale without re-architecting their payments stack. "Tok
RE Royalties Announces Annual Grant of Stock Options and Restricted Share Units20.1.2026 00:00:00 CET | Press release
All amounts in Canadian dollars unless otherwise stated VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / RE Royalties Ltd. (TSXV:RE)(OTCQX:RROYF)(FSE:Y2V) ("RE Royalties" or the "Company") is pleased to announce that, as part of the Company's annual compensation review, the Board of Directors have authorized the grant of 1,195,000 stock options (the "Options") to directors, officers, employees and consultants of the Company. The Options have an exercise price of CAD $0.30 per share and are exercisable for a period of three-years from the date of grant. The Options were granted in accordance with the Company's Stock Option Plan. In addition, the Board of Directors have authorized the grant of an aggregate 800,000 restricted share units ("RSUs") to officers, employees and consultants of the Company. The RSUs were granted in accordance with the Company's RSU Plan in place. "We are pleased to provide these incentive-based equity awards to our valued team members," said Bernard Tan, CEO
GA-ASI and Barzan Holdings Sign MOU19.1.2026 18:00:00 CET | Press release
Companies Will Collaborate on the Development of Advanced Battle Management DOHA, QA / ACCESS Newswire / January 19, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) -- the world leader in unmanned systems - and Barzan Holdings, Qatar's national defence and security leader, signed a Memorandum of Understanding (MOU) to collaborate on the development of advanced Battle Management software capabilities. The signing took place on Monday during the Doha International Maritime Defence Exhibition and Conference (DIMDEX). The MOU provides a framework for cooperation between GA-ASI, GA-Intelligence, and Barzan Holdings to develop software solutions that enhance theater-level situational awareness and enable the efficient processing, correlation, and dissemination of intelligence. These capabilities are intended to support faster, higher-quality decision-making in complex, multi-domain operational environments. For General Atomics, the agreement underscores the strategic importance of
GA-ASI Makes Another Autonomous Aerial Intercept in Company-Funded Demo with MQ-20 Avenger(R)19.1.2026 03:00:00 CET | Press release
SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 18, 2026 / In its latest demonstration of advanced autonomy development, General Atomics Aeronautical Systems, Inc. (GA-ASI) successfully executed a mission autonomy flight using its MQ-20 Avenger® jet equipped with the latest government reference autonomy software. The test included a live engagement between the MQ-20 and an aggressor aircraft flown by an onboard human pilot, highlighting the advanced maturity of autonomous systems, seamless integration of mission elements, and the ability of autonomy to leverage onboard sensors to make independent decisions and execute complex tasks. GA-ASI's Avenger jet has served as a surrogate for Collaborative Combat Aircraft (CCA) for more than five years, both before and since the arrival of GA-ASI's purpose-built XQ-67A and YFQ-42A aircraft. The recent Avenger demo began with planning in the Human-Machine Interface (HMI), followed by loading the mission profile onto the MQ-20. Once airborne, th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom